Batoclimab Clinical Trials (2026): 7 Studies for Thyroid Eye Disease & Chronic Inflammatory Demyelinating Polyneuropathy
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
7 Batoclimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Thyroid Eye Disease & Chronic Inflammatory Demyelinating Polyneuropathy) and 701 total planned enrollment. 4 Phase 3 Batoclimab trials and 3 Phase 2 are listed. Most recent activity: NCT05403541 (Feb 2027).
Batoclimab clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | completed | terminated | Total |
|---|---|---|---|---|
| P2 | 1 | 2 | 3 | |
| P3 | 1 | 2 | 1 | 4 |
Batoclimab clinical trials by indication
Thyroid Eye Disease (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05517447 | — | P3 | terminated | Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease |
| NCT05524571 | — | P3 | completed | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease |
| NCT05517421 | — | P3 | completed | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease |
Chronic Inflammatory Demyelinating Polyneuropathy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05581199 | — | P2 | terminated | To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP |
| NCT07188844 | CIDP | P2 | terminated | An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Graves Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05907668 | — | P2 | completed | A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease |
Generalized Myasthenia Gravis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05403541 | — | P3 | active not recruiting | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis |
Batoclimab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| CIDP | NCT07188844 | P2 | terminated | Chronic Inflammatory Demyelinating Polyneuropathy | 26 | — |
Terminated and withdrawn Batoclimab trials (3)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05581199terminatedTo Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
- NCT07188844terminatedAn Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT05517447terminatedExtension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
All Batoclimab trials (7)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05403541 | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis | P3 | active not recruiting | 240 | Immunovant Sciences GmbH | Jun 2022 | |
| NCT05581199 | To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP | P2 | terminated | 94 | Immunovant Sciences GmbH | Dec 2022 | |
| NCT07188844 | CIDP | An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | P2 | terminated | 26 | Immunovant Sciences GmbH | Aug 2025 |
| NCT05517447 | Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease | P3 | terminated | 109 | Immunovant Sciences GmbH | Nov 2022 | |
| NCT05524571 | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease | P3 | completed | 86 | Immunovant Sciences GmbH | Jan 2023 | |
| NCT05517421 | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease | P3 | completed | 114 | Immunovant Sciences GmbH | Nov 2022 | |
| NCT05907668 | A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease | P2 | completed | 32 | Immunovant Sciences GmbH | May 2023 |
Batoclimab clinical trials: frequently asked questions
- How many Batoclimab clinical trials are there?
- 7 Batoclimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are marked completed.
- Are Batoclimab clinical trials recruiting in 2026?
- No active Batoclimab trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Batoclimab being studied for?
- Batoclimab is being studied for Thyroid Eye Disease, Chronic Inflammatory Demyelinating Polyneuropathy, Generalized Myasthenia Gravis, Graves Disease. The trials are grouped by indication on this page.
- What phase is Batoclimab in?
- Batoclimab clinical trials span 4 Phase 3, 3 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Batoclimab clinical trials?
- The lead sponsor across the most Batoclimab trials is Immunovant Sciences GmbH. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Batoclimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: